Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse

Overview of attention for article published in Frontiers in Cardiovascular Medicine, October 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (55th percentile)

So far, Altmetric has seen 5 X posts from 3 X users, with an upper bound of 25,163 followers.

Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Diabetic Mice https://t.co/i1ck3Y2QQL

メチルグリオキサールの影響。HUVECではAkt と eNOSSer1177 のリン酸化を阻害。 MCP-1, VCAM-1, and ICAM-1が高発現#AGE https://t.co/loIbTIu7Bk

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in… https://t.co/Oj87NGqo2i

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.